Gary Prestopino, an analyst from Barrington, maintained the Buy rating on PaySign (PAYS – Research Report). The associated price target remains the same with $6.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gary Prestopino has given his Buy rating due to a combination of factors that highlight PaySign’s strong growth potential and strategic positioning in the healthcare industry. The company’s Pharma Patient Affordability segment is a key driver of growth, having significantly increased its revenue and improved its margin profile. This segment has shown impressive expansion, adding new programs and supporting a wide range of therapeutic areas, with expectations of doubling its revenue in the coming year.
Additionally, PaySign’s recent business win in the Plasma segment, involving the onboarding of numerous plasma donation centers, is expected to contribute substantially to revenue without a proportional increase in expenses. The acquisition of Gamma Innovation further strengthens PaySign’s technological capabilities and market position. These developments, combined with the company’s updated guidance reflecting increased revenue and EBITDA expectations, underpin Prestopino’s positive outlook and the Buy rating for PaySign’s stock.
In another report released on June 11, Lake Street also reiterated a Buy rating on the stock with a $7.00 price target.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is neutral on the stock.